Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy combo shows promise against stomach cancer

NCT ID NCT03675737

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This large Phase 3 trial tested adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy for people with advanced stomach cancer that cannot be removed by surgery. Over 1,500 participants received either pembrolizumab plus chemo or a placebo plus chemo. The main goal was to see if the combination helped people live longer. Results showed improved overall survival, especially in patients with higher PD-L1 levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pembrolizumab (Keytruda) plus chemotherapy (cisplatin/5-fluorouracil or oxaliplatin/capecitabine)
What this could lead to
If successful, this combination could become a new standard first-line treatment for advanced stomach cancer, helping patients live longer.
What could go wrong
This trial is completed and showed benefits, but not all patients respond. Side effects from chemo and immunotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,579 people

The number who actually took part.

Started

Nov 2018

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Has histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma with known programmed cell death ligand 1 (PD-L1) expression status * Has human epidermal growth factor receptor 2 (HER2) negative cancer * Male participants must agree to use contraception during the treatment period and through 95 days after the last dose of chemotherapy, refrain from donating sperm, and be abstinent from heterosexual intercourse, as their preferred and usual lifestyle, and agree to remain abstinent or must agree to use contraception per study protocol unless confirmed to be azoospermic during this period * Female participants who are not pregnant, not breastfeeding, and at least one of the following conditions applies: not a woman of childbearing potential (WOCBP) OR is a WOCBP who agrees to use contraception or be abstinent from heterosexual intercourse, as their preferred and usual lifestyle, during the treatment period and through 180 days after the last dose of chemotherapy or through 120 days after the last dose of pembrolizumab, whichever is last, and agrees not to donate eggs to others or freeze/store for her own use for the purpose of reproduction during this period * Has measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator assessment * Has provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated * Has provided tumor tissue sample deemed adequate for PD-L1 biomarker analysis * Has provided tumor tissue sample for microsatellite instability (MSI) biomarker analysis * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 3 days prior to the start of study intervention * Has adequate organ function as demonstrated by laboratory testing within 10 days prior to the start of study treatment Exclusion Criteria * Has squamous cell or undifferentiated gastric cancer * Has had major surgery, open biopsy, or significant traumatic injury within 28 days prior to randomization, anticipation of the need for major surgery during the course of study intervention, or has not recovered adequately from the toxicity and/or complications from previous surgery * Has preexisting peripheral neuropathy \>Grade 1 * Is a WOCBP who has a positive urine pregnancy test within 24 hours for urine or within 72 hours for serum prior to randomization or treatment allocation * Has had previous therapy for locally advanced, unresectable or metastatic gastric/GEJ cancer. Participants may have received prior neoadjuvant and/or adjuvant therapy as long as it was completed ≥6 months prior to randomization * Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1 or anti-programmed cell death ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX- 40, CD137) * Has received prior systemic anticancer therapy including investigational agents within 4 weeks prior to randomization or has not recovered from all adverse events (AEs) due to any previous therapies to ≤Grade 1 or baseline * Has received prior radiotherapy within 2 weeks prior to study start or has not recovered from all previous radiation-related toxicities, required corticosteroids, and have not had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease * Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study treatment * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment * Has a known additional malignancy that is progressing or has required active treatment within the past 5 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy * Has known active CNS metastases and/or carcinomatous meningitis * Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients * Has an active autoimmune disease that has required systemic treatment in past 2 years * Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis * Has an active infection requiring systemic therapy * Has a known history of human immunodeficiency virus (HIV) infection * Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as Hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] detected qualitatively) infection * Has a known history of active tuberculosis * Has hypokalemia (serum potassium less than the lower limit of normal) * Has hypomagnesemia (serum magnesium less than the lower limit of normal) * Has hypocalcemia (serum calcium less than the lower limit of normal) * Has a history or current evidence of any condition (eg, known deficiency of the enzyme dihydropyrimidine dehydrogenase), therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator * Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study * Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of chemotherapy or through 120 days after the last dose of pembrolizumab, whichever is last * Has had an allogenic tissue/solid organ transplant * Has a known severe hypersensitivity (≥ Grade 3) to any of the study chemotherapy agents (including, but not limited to, infusional 5-fluorouracil or oral capecitabine) and/or to any of their excipients * For participants taking cisplatin: has Grade ≥2 audiometric hearing loss

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2 negative advanced gastric adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 gastric adenocarcinoma gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stomach neoplasms

Contacts and locations

Locations

  • 1st Affil hosp of Med College of Xi'an Jiaotong University ( Site 2428)

    XiAn, Shanxi, 710061, China

  • 900 Hospital of the Joint ( Site 2418)

    Fuzhou, Fujian, 350025, China

  • Aalborg University Hospital ( Site 3204)

    Aalborg, North Denmark, 9000, Denmark

  • Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi ( Site 2006)

    Ankara, 06200, Turkey (Türkiye)

  • Adana Sehir Hastanesi ( Site 2002)

    Adana, 01370, Turkey (Türkiye)

  • Aichi Cancer Center Hospital ( Site 2619)

    Nagoya, Aichi-ken, 464-8681, Japan

  • Allegheny General Hospital ( Site 0118)

    Pittsburgh, Pennsylvania, 15212, United States

  • Asan Medical Center ( Site 2802)

    Seoul, 05505, South Korea

  • Asklepios Klinik Altona ( Site 1100)

    Hamburg, 22763, Germany

  • Ataturk Universitesi Tip Fakultesi Hastanesi ( Site 2000)

    Erzurum, 25240, Turkey (Türkiye)

  • Auckland City Hospital ( Site 2700)

    Auckland, Northland, 1023, New Zealand

  • Azienda Ospedaliera San Camillo Forlanini ( Site 1413)

    Roma, 00152, Italy

  • BC Cancer - Abbotsford ( Site 0206)

    Abbotsford British Columbia, British Columbia, V2S 0C2, Canada

  • Bacs-Kiskun Megyei Korhaz ( Site 3306)

    Kecskemét, Bács-Kiskun county, 6000, Hungary

  • Beaumont Hospital ( Site 2101)

    Dublin, D09V2N0, Ireland

  • Blokhin National Medical Oncology ( Site 1604)

    Moscow, Moscow, 115478, Russia

  • Box Hill Hospital ( Site 2300)

    Box Hill, Victoria, 3128, Australia

  • C.H.R.U. de Brest - Hopital Morvan ( Site 1007)

    Brest, Finistere, 29200, France

  • CEPON - Centro de Pesquisas Oncologicas ( Site 0400)

    Florianópolis, Santa Catarina, 88034-000, Brazil

  • CHU Hopital Saint Antoine ( Site 1001)

    Paris, 75012, France

  • CHU de Rouen ( Site 1006)

    Rouen, Ain, 76000, France

  • CHU-Jean Minjoz ( Site 1002)

    Besançon, Doubs, 25030, France

  • CIMCA Centro de Investigacion y Manejo del Cancer ( Site 3001)

    San José, 10103, Costa Rica

  • CIONC - Centro Integrado de Oncologia de Curitiba ( Site 0405)

    Curitiba, Paraná, 80810-050, Brazil

  • Cancer Care Langenhoven Drive Oncology Centre ( Site 1708)

    Port Elizabeth, Eastern Cape, 6045, South Africa

  • Cancer Hospital Affiliated to Xinjiang Medical University ( Site 2420)

    Ürümqi, Xinjiang, 830001, China

  • Cancer Hospital Chinese Academy of Medical Sciences ( Site 2421)

    Beijing, Beijing Municipality, 100021, China

  • Cancer Treatment Centers of America - Philadelphia ( Site 0112)

    Philadelphia, Pennsylvania, 19124, United States

  • Cancercare Rondebosch Oncology ( Site 1709)

    Cape Town, Western Cape, 7700, South Africa

  • Cape Town Oncology Trials Pty Ltd ( Site 1703)

    Kraaifontein, Western Cape, 7570, South Africa

  • Castle Hill Hospital ( Site 1201)

    Cottingham, East Riding Of Yorkshire, HU16 5JQ, United Kingdom

  • Celan SA ( Site 0705)

    Guatemala City, 01010, Guatemala

  • Central Clinical Hospital with Polyclinic ( Site 1614)

    Moscow, Moscow, 121359, Russia

  • Centre Oscar Lambret ( Site 1003)

    Lille, Nord, 59000, France

  • Centro Medico Imbanaco de Cali S.A ( Site 0604)

    Cali, Valle del Cauca Department, 760042, Colombia

  • Centro Oncologico Riojano Integral ( Site 0313)

    La Rioja, F5300COE, Argentina

  • Centro Regional de Sub Especialidades Medicas SA ( Site 0703)

    Quetzaltenango, 09001, Guatemala

  • Chaim Sheba Medical Center ( Site 1304)

    Ramat Gan, Tel Aviv, 5266202, Israel

  • Chang Gung Medical Foundation. Kaohsiung Branch ( Site 2902)

    Kaohsiung City, 83301, Taiwan

  • Changzhou Cancer Hospital-Changzhou Fourth Peoples Hospital ( Site 2441)

    Changzhou, Jiangsu, 213032, China

  • Charite Universitaetsmedizin Berlin ( Site 1101)

    Berlin, 13353, Germany

  • Chelyabinsk Regional Clinical Oncology Dispensary-Chemotherapy ( Site 1608)

    Chelyabinsk, Chelyabinsk Oblast, 454087, Russia

  • Christus Muguerza Clinica Vidriera ( Site 0802)

    Monterrey, Nuevo León, 64570, Mexico

  • City Clinical Hosp.4 of DCC ( Site 2201)

    Dnipro, Dnipropetrovsk Oblast, 49102, Ukraine

  • City Clinical Oncology Center ( Site 1603)

    Saint Petersburg, Sankt-Peterburg, 198255, Russia

  • Clinic of National Cancer Institute ( Site 2203)

    Kyiv, Kyivska Oblast, 03022, Ukraine

  • Clinica Ricardo Palma Instituto de Oncologia y Radioterapia ( Site 0908)

    Lima, 15036, Peru

  • Clinica San Gabriel ( Site 0907)

    Lima, 15088, Peru

  • Communal non profit enterprise Regional Clinical Oncology Center ( Site 2208)

    Kharkiv, Kharkiv Oblast, 61070, Ukraine

  • Dokuz Eylul Universitesi Tip Fakultesi Hastanesi ( Site 2011)

    Izmir, 35340, Turkey (Türkiye)

  • Dolnoslaskie Centrum Onkologii we Wroclawiu ( Site 1504)

    Wroclaw, Lower Silesian Voivodeship, 53-413, Poland

  • Edith Wolfson Medical Center ( Site 1307)

    Holon, Tell Abib, 5822012, Israel

  • FN Ostrava ( Site 3105)

    Ostrava, Moravian-Silesian Region, 708 52, Czechia

  • Facharztzentrum Eppendorf ( Site 1121)

    Hamburg, 20249, Germany

  • Fakultni Thomayerova nemocnice ( Site 3101)

    Prague, 140 59, Czechia

  • Fakultni nemocnice Olomouc ( Site 3100)

    Olomouc, 779 00, Czechia

  • Fakultni nemocnice Plzen ( Site 3102)

    Pilsen, Plzeň Region, 304 60, Czechia

  • Fourth Hospital Of Hebei Medical University ( Site 2436)

    Shijiazhuang, Hebei, 050011, China

  • Fujian Medical University Union Hospital ( Site 2410)

    Fuzhou, Fujian, 350001, China

  • Fujian Provincial Cancer Hospital ( Site 2414)

    Fuzhou, Fujian, 350014, China

  • Fundacion Arturo Lopez Perez FALP ( Site 0501)

    Santiago, Region M. de Santiago, 7500921, Chile

  • Fundacion Favaloro - Hospital Universitario ( Site 0302)

    Buenos Aires, C1093AAS, Argentina

  • Greater Baltimore Medical Center ( Site 0102)

    Baltimore, Maryland, 21204, United States

  • Groote Schuur Hospital ( Site 1706)

    Cape Town, Western Cape, 7925, South Africa

  • Grupo Angeles SA ( Site 0701)

    Guatemala City, 01015, Guatemala

  • Guangdong General Hospital ( Site 2431)

    Guangzhou, Guangdong, 510080, China

  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1805)

    Pozuelo de Alarcón, Madrid, 28223, Spain

  • Hacettepe University Medical Faculty ( Site 2017)

    Ankara, 06100, Turkey (Türkiye)

  • Hadassah Ein Karem Jerusalem ( Site 1301)

    Jerusalem, Jerusalem, 9112001, Israel

  • Harbin Medical University Cancer Hospital ( Site 2401)

    Harbin, Heilongjiang, 150081, China

  • Henan Cancer Hospital ( Site 2415)

    Zhengzhou, Henan, 450008, China

  • Hiroshima City Hiroshima Citizens Hospital ( Site 2611)

    Hiroshima, 730-8518, Japan

  • Hopitaux Universitaires de Geneve HUG ( Site 1907)

    Geneva, Canton of Geneva, 1211, Switzerland

  • Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0808)

    Guadalajara, Jalisco, 44280, Mexico

  • Hospital General Universitari Vall d Hebron ( Site 1801)

    Barcelona, 08035, Spain

  • Hospital General Universitario de Elche ( Site 1803)

    Elche, Alicante, 03203, Spain

  • Hospital Nacional Arzobispo Loayza ( Site 0902)

    Lima, 15082, Peru

  • Hospital Nossa Senhora da Conceicao ( Site 0403)

    Porto Alegre, Rio Grande do Sul, 91350-200, Brazil

  • Hospital Universitario General de Asturias ( Site 1802)

    Oviedo, Principality of Asturias, 33011, Spain

  • Hospital Universitario Marques de Valdecilla ( Site 1804)

    Santander, Cantabria, 39008, Spain

  • Hospital de Caridade de Ijui ( Site 0402)

    Ijuí, Rio Grande do Sul, 98700 000, Brazil

  • Hubei Cancer Hospital ( Site 2434)

    Wuhan, Hubei, 430079, China

  • Hunan Cancer Hospital ( Site 2439)

    Changsha, Hunan, 410013, China

  • Hyogo Cancer Center ( Site 2604)

    Akashi, Hyōgo, 673-8558, Japan

  • IBCC - Instituto Brasileiro de Controle do Cancer ( Site 0404)

    São Paulo, 03102-002, Brazil

  • ICIMED - Instituto de Investigacion en Ciencias Medicas ( Site 3000)

    San José, 10108, Costa Rica

  • Ibaraki Prefectural Central Hospital ( Site 2610)

    Kasama, Ibaraki, 309-1793, Japan

  • Institut Catala d Oncologia Hospital Germans Trias i Pujol ( Site 1806)

    Badalona, Barcelona, 08916, Spain

  • Institut Gustave Roussy ( Site 1000)

    Villejuif, Val-de-Marne, 94805, France

  • Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 1004)

    Saint-Herblain, Val-de-Marne, 44805, France

  • Instituto Clinico Oncologico del Sur ( Site 0500)

    Temuco, Araucania, 4810469, Chile

  • Instituto Medico Alexander Fleming ( Site 0307)

    Buenos Aires, Buenos Aires F.D., C1426ANZ, Argentina

  • Instituto Nacional de Cancerologia E.S.E ( Site 0605)

    Bogotá, Bogota D.C., 110321, Colombia

  • Instituto Nacional de Cancerologia. ( Site 0804)

    Mexico City, 14080, Mexico

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 0806)

    Mexico City, 14080, Mexico

  • Instituto Nacional de Enfermedades Neoplasicas ( Site 0901)

    Lima, 15038, Peru

  • Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0401)

    Rio de Janeiro, 20231-050, Brazil

  • Instituto San Marcos ( Site 0311)

    San Juan, J5400EBB, Argentina

  • Instituto de Investigaciones Metabolicas ( Site 0312)

    Buenos Aires, C1012AAR, Argentina

  • Instituto do Cancer do Ceara ( Site 0407)

    Fortaleza, Ceará, 60430-230, Brazil

  • Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 2001)

    Istanbul, 34098, Turkey (Türkiye)

  • Istituto Europeo di Oncologia ( Site 1411)

    Milan, Lombardy, 20141, Italy

  • Istituto Nazionale dei Tumori Fondazione IRCSS ( Site 1402)

    Milan, 20133, Italy

  • Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1905)

    Bellinzona, Canton Ticino, 6500, Switzerland

  • Istituto Oncologico Veneto ( Site 1412)

    Padova, 35128, Italy

  • Jasz-Nagykun-Szolnok Megyei Hetenyi Gyula Korhaz-Rendelointezet ( Site 3302)

    Szolnok, Jász-Nagykun-Szolnok, 5004, Hungary

  • Jiangsu Cancer Hospital ( Site 2432)

    Nanjing, Jiangsu, 210009, China

  • Kagawa University Hospital ( Site 2615)

    Kita-gun, Kagawa-ken, 761-0793, Japan

  • Kanagawa Cancer Center ( Site 2614)

    Yokohama, Kanagawa, 241-8515, Japan

  • Kansai Medical University Hospital ( Site 2608)

    Hirakata, Osaka, 573-1191, Japan

  • Kantonsspital Graubuenden ( Site 1903)

    Chur, Kanton Graubünden, 7000, Switzerland

  • Kantonsspital St. Gallen ( Site 1901)

    Sankt Gallen, Canton of St. Gallen, 9007, Switzerland

  • Kindai University Hospital ( Site 2616)

    Sayama, Osaka, 589-8511, Japan

  • Kitasato University Hospital ( Site 2618)

    Sagamihara, Kanagawa, 252-0375, Japan

  • Kobe City Medical Center General Hospital ( Site 2603)

    Kobe, Hyōgo, 650-0047, Japan

  • Kumamoto University Hospital ( Site 2602)

    Kumamoto, 860-8556, Japan

  • Kyiv City Clinical Oncology Centre ( Site 2213)

    Kyiv, 03115, Ukraine

  • Liverpool Hospital ( Site 2301)

    Liverpool, New South Wales, 2170, Australia

  • Luzern Kantonsspital ( Site 1904)

    Lucerne, 6000, Switzerland

  • Lviv State Oncology Regional Treatment and Diagnostic Center ( Site 2210)

    Lviv, Lviv Oblast, 79031, Ukraine

  • MEDI-K CAYALA ( Site 0704)

    Guatemala City, 01016, Guatemala

  • MI Kryviy Rih Center of Dnipropetrovsk Regional Council ( Site 2200)

    Kryviy Rih, Dnipropetrovsk Oblast, 50048, Ukraine

  • MI Odessa Regional Oncological Centre ( Site 2212)

    Odesa, Odesa Oblast, 65055, Ukraine

  • MI Precarpathian Clinical Oncology Center ( Site 2204)

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76018, Ukraine

  • Mackay Memorial Hospital ( Site 2903)

    Taipei, 104, Taiwan

  • Magodent Szpital Elblaska ( Site 1509)

    Warsaw, Masovian Voivodeship, 01-748, Poland

  • Malatya Inonu Universitesi Tip Fakultesi Hastanesi ( Site 2009)

    Malatya, 44280, Turkey (Türkiye)

  • Masarykuv onkologicky ustav ( Site 3103)

    Brno, South Moravian, 65653, Czechia

  • McGill University Health Centre ( Site 0208)

    Montreal, Quebec, H4A 3J1, Canada

  • Medical Care and Research S.A. de C.V. ( Site 0809)

    Mérida, 97070, Mexico

  • Medical Centre LLC Oncolife ( Site 2202)

    Zaporizhzhya, Zaporizhzhia Oblast, 69104, Ukraine

  • Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 2205)

    Kyiv, Kyivska Oblast, 03126, Ukraine

  • Meir Medical Center ( Site 1308)

    Kfar Saba, 4428164, Israel

  • Minnesota Oncology Hematology, PA ( Site 8000)

    Minneapolis, Minnesota, 55404, United States

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • National Cancer Center Hospital ( Site 2606)

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East ( Site 2617)

    Kashiwa, Chiba, 277-8577, Japan

  • National Cheng Kung University Hospital ( Site 2901)

    Tainan, 70457, Taiwan

  • National Hospital Organization Kyushu Cancer Center ( Site 2612)

    Fukuoka, 811-1395, Japan

  • National Taiwan University Hospital ( Site 2900)

    Taipei, 100225, Taiwan

  • Nemocnice AGEL Novy Jicin a.s. ( Site 3104)

    Nový Jičín, 74101, Czechia

  • Niigata Cancer Center Hospital ( Site 2613)

    Niigata, 951-8566, Japan

  • Odense Universitets Hospital ( Site 3201)

    Odense, Region Syddanmark, 5000, Denmark

  • Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care ( Site 8001)

    Roanoke, Virginia, 24014, United States

  • Oncomedica ( Site 0702)

    Guatemala City, 01010, Guatemala

  • Oncomedica S.A. ( Site 0606)

    Montería, Departamento de Córdoba, 230002, Colombia

  • Orszagos Onkologiai Intezet ( Site 3303)

    Budapest, 1122, Hungary

  • Osaka International Cancer Institute ( Site 2607)

    Osaka, 541-8567, Japan

  • Osaka University Hospital ( Site 2600)

    Suita, Osaka, 565-0871, Japan

  • Outeniqua Cancercare Oncology Unit ( Site 1704)

    George, Western Cape, 6530, South Africa

  • Peking Union Medical College Hospital ( Site 2425)

    Beijing, Beijing Municipality, 100730, China

  • Peking University Shenzhen Hospital ( Site 2442)

    Shenzhen, Guangdong, 518036, China

  • Policlinico San Bosco ( Site 3002)

    San José, 10103, Costa Rica

  • Pontificia Universidad Catolica de Chile ( Site 0502)

    Santiago, Region M. de Santiago, 7620002, Chile

  • Prince of Wales Hospital ( Site 2503)

    Hong Kong, Hong Kong

  • Princess Margaret Cancer Centre ( Site 0203)

    Toronto, Ontario, M5G 2M9, Canada

  • Princess Margaret Hospital. ( Site 2502)

    Hong Kong, Hong Kong

  • Przychodnia Lekarska Komed ( Site 1514)

    Konin, Greater Poland Voivodeship, 62-500, Poland

  • Queen Mary Hospital ( Site 2501)

    Hong Kong, Hong Kong

  • Rabin Medical Center ( Site 1302)

    Petah Tikva, 4941492, Israel

  • Rambam Medical Center ( Site 1303)

    Haifa, 3109601, Israel

  • Regionalny Szpital Specjalistyczny im Wl. Bieganskiego w Grudziadzu ( Site 1505)

    Grudziądz, 86-300, Poland

  • Rigshospitalet ( Site 3202)

    Copenhagen, Capital Region, 2100, Denmark

  • SBHI Leningrad Regional Clinical Hospital ( Site 1616)

    Saint Petersburg, Leningradskaya Oblast', 194291, Russia

  • SBHI Samara Regional Clinical Oncology Dispensary ( Site 1609)

    Samara, Samara Oblast, 443031, Russia

  • SLK-Kliniken Heilbronn ( Site 1104)

    Heilbronn, Baden-Wurttemberg, 74078, Germany

  • Saitama Cancer Center ( Site 2601)

    Kitaadachi-gun, Saitama, 362-0806, Japan

  • Sakarya Universitesi Egitim ve Arastirma Hastanesi ( Site 2012)

    Sakarya, 54000, Turkey (Türkiye)

  • Samsung Medical Center ( Site 2801)

    Seoul, 06351, South Korea

  • Sandton Oncology Medical Group PTY LTD ( Site 1700)

    Johannesburg, Gauteng, 2196, South Africa

  • Semmelweis Egyetem.. ( Site 3305)

    Budapest, 1083, Hungary

  • Seoul National University Hospital ( Site 2803)

    Seoul, 03080, South Korea

  • Severance Hospital Yonsei University Health System ( Site 2800)

    Seoul, 03722, South Korea

  • Shanghai East Hospital ( Site 2403)

    Shanghai, Shanghai Municipality, 200120, China

  • Sir Run Run Show Hospital ( Site 2427)

    Hangzhou, Zhejiang, 310016, China

  • Sociedad Oncovida S.A. ( Site 0508)

    Santiago, Region M. de Santiago, 7510032, Chile

  • Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0608)

    Valledupar, Cesar Department, 200001, Colombia

  • Soroka University Medical Center ( Site 1305)

    Beersheba, 8410101, Israel

  • Sourasky Medical Center ( Site 1306)

    Tel Aviv, Tell Abib, 6423906, Israel

  • South Devon Healthcare Foundation Trust. Torbay Hospital ( Site 1205)

    Torquay, Devon, TQ2 7AA, United Kingdom

  • Southern Medical Day Care Centre ( Site 2303)

    Wollongong, New South Wales, 2500, Australia

  • St. Georges University Hospital NHS Foundation Trust ( Site 1204)

    London, London, City of, SW17 0QT, United Kingdom

  • St. James s Hospital ( Site 1200)

    Dublin, D08 W9RT, Ireland

  • Sunnybrook Research Institute ( Site 0202)

    Toronto, Ontario, M4N 3M5, Canada

  • Szpital Uniwersytecki w Krakowie ( Site 1503)

    Krakow, Lesser Poland Voivodeship, 31-501, Poland

  • Tallaght University Hospital ( Site 1202)

    Dublin, D24 NR0A, Ireland

  • The 81st Hospital of PLA ( Site 2413)

    Nanjing, Jiangsu, 210002, China

  • The Affiliated Hospital of Qingdao University ( Site 2405)

    Qingdao, Shandong, 266061, China

  • The Cancer Institute Hospital of JFCR ( Site 2609)

    Tokyo, 135-8550, Japan

  • The First Affiliated Hospital of Nanchang University ( Site 2440)

    Nanchang, Jiangxi, 330006, China

  • The First Affiliated Hospital of Xiamen University ( Site 2430)

    Xiamen, Fujian, 361003, China

  • The First Hospital of Jilin University ( Site 2416)

    Changchun, Jilin, 130021, China

  • The Oncology Centre Overport and Umhlanga ( Site 1705)

    Durban, KwaZulu-Natal, 4091, South Africa

  • Tokyo Metropolitan Komagome Hospital ( Site 2605)

    Tokyo, 113-8677, Japan

  • Trakya Universitesi Tip Fakultesi ( Site 2015)

    Edirne, 22030, Turkey (Türkiye)

  • Tshwane District Hospital ( Site 1702)

    Pretoria, Gauteng, 0002, South Africa

  • UC Irvine Health/Division of Hematology Oncology, Dept of Medicine ( Site 0128)

    Orange, California, 92868, United States

  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) ( Site 0124)

    Los Angeles, California, 90095, United States

  • Universitaetsklinikum Leipzig ( Site 1114)

    Leipzig, Saxony, 04103, Germany

  • Universitaetsspital Basel ( Site 1900)

    Basel, Canton of Basel-City, 4056, Switzerland

  • Universitaetsspital Zuerich ( Site 1902)

    Zurich, Canton of Zurich, 8091, Switzerland

  • Universitas Annex National Hospital ( Site 1701)

    Bloemfontein, Free State, 9301, South Africa

  • University College London Hospital ( Site 1211)

    London, London, City of, NW1 2PG, United Kingdom

  • University of Debrecen Medical Center Clinic of Oncology ( Site 3300)

    Debrecen, 4032, Hungary

  • University of Miami, Sylvester Comprehensive Cancer Center ( Site 0113)

    Miami, Florida, 33136, United States

  • University of Rochester ( Site 0122)

    Rochester, New York, 14642, United States

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 1506)

    Wroclaw, Lower Silesian Voivodeship, 50-556, Poland

  • Wenatchee Valley Clinic [Wenatchee, WA] ( Site 0116)

    Wenatchee, Washington, 98801, United States

  • Wits Clinical Research ( Site 1707)

    Parktown-Johannesburg, Gauteng, 2193, South Africa

  • Xiangya Hospital Central-South University ( Site 2419)

    Changsha, Hunan, 410008, China

  • Yancheng First People s Hospital ( Site 2426)

    Yancheng, Jiangsu, 224000, China

  • Zhejiang Cancer Hospital ( Site 2417)

    Hangzhou, Zhejiang, 310022, China

  • Zhejiang Provincial People's Hospital ( Site 2446)

    Hangzhou, Zhejiang, 310014, China

  • Zhongshan Hospital Xiamen University ( Site 2447)

    Xiamen, Fujian, 361004, China

  • Zhongshan Hospital affiliated to Fudan University ( Site 2407)

    Shanghai, Shanghai Municipality, 210000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.